Recent Updates
Recently added Catalysts

Peptide YY3-36

Phase 1

Obesity | Small molecule | Metabolic |Pfizer, Inc.|Last Updated: Dec 15, 2006

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedUNCONTROLLED
Total Trials1
Total Enrollment31
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00331175Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight AdultsPHASE1 COMPLETED 31Jul 1, 2006Dec 1, 2006Dec 15, 20061 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Food intake
Secondary Endpoints
Plasma biomarkers, safety, toleration
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelCROSSOVER
PurposeTREATMENT
Interventions
NameTypeDescription
Peptide YY3-36DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * BMI 27-35 kg/m2 Exclusion Criteria: * Women of childbearing potential

Countries:United States
Unlock Eligibility Criteria